Table 1.

Tumorigenicity and serial transplantability of PC3-GFP cell clones

CloneCellTumor incidence *Mean tumor weight (g) Termination (d)
PC31001/8 (13%)ND90 (33)
1,0005/8 (63%)ND75 (33)
10,0008/8 (100%)ND60 (18)
100,0007/8 (88%)ND45 (18)
PC3-GFP10,0007/8 (88%)1.1165 (24)
100,0006/8 (75%)1.3755 (11)
P3C4 (holoclone)
10,0008/8 (100%)0.3770 (24)
    2°1,0008/10 (80%)0.3969 (26)
    3°1,0009/10 (90%)0.5147 (26)
P1E2 (holoclone)1,0008/10 (80%)0.2175 (54)
10,0009/10 (90%)1.4175 (47)
    2°1,0005/6 (83%)0.2255 (35)
    3°1,0007/8 (88%)0.1949 (29)
P1H8 (holoclone)1,0008/10 (80%)0.2769 (36)
10,00010/10 (100%)1.3969 (28)
    2°1,0006/6 (100%)1.0671 (39)
P2A12 (meroclone)10,0000/100187
100,0000/20187
P2H3 (meroclone)10,0000/90121
100,0000/20121
P2D4 (paraclone)1,0000/1063
  • NOTE: PC3 or PC3-GFP cells, or PC3-GFP cell clones at the indicated numbers were injected in 50% Matrigel into the flanks of NOD/SCID mice. Secondary (2°) and tertiary (3°) serial transplantation experiments were performed as described in the text.

    Abbreviation: ND, not determined.

  • * The number of tumors developed/number of injections.

  • Mean tumor weight in grams.

  • Time in days when animals were terminated and the tumor was harvested. The numbers in parentheses are latency (i.e., when tumors were first detected after implantation).